25,457 shares were delivered or withheld at Treace Medical (TMCI), leaving 753,226 directly held.
Scot Michael Elder, Chief Legal & Compliance Officer and Corporate Secretary at Treace Medical Concepts, Inc. (TMCI), had 25,457 shares delivered or withheld on September 30, 2026, for tax liability or exercise price payment. Following this transaction, his direct holdings in the company totaled 753,226 shares, which include 524,030 restricted stock units. This transaction was reported in a Form 4 SEC filing.
Form 4 Treace Medical Concepts Inc For: 2 October By Investing.com
This article announces the filing of Form 4 for Treace Medical Concepts Inc. on October 2nd, as reported by Investing.com. It is a brief, informative post indicating a regulatory filing has occurred for the company. The article contains minimal descriptive text beyond the headline.
Treace Medical Concepts Inc (TMCI-Q) Stock Price and News
This page provides stock price and news updates for Treace Medical Concepts Inc (TMCI-Q). It includes real-time stock data, historical performance charts, dividend information, analyst ratings, financial reports, and a feed of recent news articles related to the company, highlighting earnings calls, product launches, and analyst recommendations. The company is described as a commercial-stage orthopedic medical device firm focused on treating Hallux Valgus.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Stock Has Consensus Target Price of $5.17 According to Brokerages
Seven research firms have given Treace Medical Concepts (NASDAQ:TMCI) a consensus "Reduce" rating with an average 12-month price target of $5.17, which is higher than its current share price of $4.62. The company recently reported better-than-expected quarterly results but remains unprofitable, with analysts expecting a full-year loss. CEO John Treace and institutional investors have increased their holdings in the company.
Bank of America Corp DE Acquires 3,305,100 Shares of Treace Medical Concepts, Inc. $TMCI
Bank of America Corp DE has acquired a significant new stake of 3.31 million shares in Treace Medical Concepts, Inc. (NASDAQ:TMCI), valued at approximately $13.15 million, representing a 5.08% ownership. This move comes as institutional investors collectively own a substantial portion of the company, and insiders have also been increasing their holdings. Despite recent positive quarterly revenue and EPS, analysts maintain a cautious "Reduce" rating for TMCI.
Investigation launched into Treace Medical officers for possible breach of shareholder duties
Halper Sadeh LLC is investigating potential breaches of fiduciary duties by officers and directors of Treace Medical Concepts, Inc. The investigation encourages long-term shareholders to seek corporate reforms or financial relief, emphasizing the limited time to act. This initiative aims to protect investor interests and improve company governance, with a market snapshot showing mixed performance in the health sector.
Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?
Treace Medical (NASDAQ: TMCI) has announced five-year ALIGN3D results for its Lapiplasty bunion-correction procedure, showing durable outcomes in a study with 137 of 173 original patients. While the evidence supports sustained alignment and patient improvement, the lack of a comparison group and missing patient data for the final analysis limit its conclusiveness. The commercial success will depend on whether this data can drive broader surgeon adoption and translate into improved revenue and margins for the company.
Treace Medical (TMCI) Reports Five-Year Bunion Results. Can Evidence Drive Adoption?
Treace Medical Concepts (TMCI) announced five-year results for its Lapiplasty bunion-correction procedure, showing a low radiographic recurrence rate of 0.8% (for cases greater than 20 degrees) and clinically meaningful improvements in patient outcomes. While this long-term data strengthens the case for Lapiplasty's durability, challenges remain in proving superiority over competing procedures and translating clinical evidence into increased revenue and profitability for the company.
96.6% of patients showed healing after foot surgery
Treace Medical Concepts (TMCI) announced positive results from three clinical studies for its Lapiplasty®, Adductoplasty®, and SpeedPlate® technologies, presented at the 2026 AOFAS Annual Meeting. Key findings include sustained outcomes for Lapiplasty over five years with low recurrence, early weight-bearing and maintained corrections for Adductoplasty, and high healing rates (96.6%) for SpeedPlate. These studies demonstrate the durability and clinical value of Treace's surgical solutions for bunions and other foot conditions.
Treace Medical Concepts Presents 5-Year ALIGN3D, 2-Year MTA3D and SPRINT Clinical Study Results at AOFAS Annual Meeting
Treace Medical Concepts announced the presentation of positive results from three clinical studies at the AOFAS Annual Meeting, highlighting the effectiveness of their bunion and foot condition treatments. The studies demonstrated low recurrence rates, early weight-bearing, and significant improvements in patient-reported outcomes for their ALIGN3D®, MTA3D®, and SPRINT™ procedures. These findings reinforce Treace's commitment to innovation and improving surgical outcomes for patients.
Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting
Treace Medical Concepts, Inc. is showcasing new product innovations and presenting clinical data at the 2026 AOFAS Annual Meeting. The company is expanding its portfolio in foot and ankle conditions, featuring advancements in 3D bunion correction systems like the Lapiplasty® Lightning™ System, and new entries into the mid and hindfoot markets with products such as SuperBite™ Fully-Threaded Compression Screws and HyperPlate™ XM. Clinical data from landmark studies (ALIGN3D®, MTA3D®, SPRINT™) will also be presented, highlighting the performance of Treace technologies.
Treace Medical Concepts to Showcase New Foot and Ankle Innovations and Clinical Data at AOFAS 2026
Treace Medical Concepts, Inc. will participate in the American Orthopaedic Foot & Ankle Society Annual Meeting in Seattle from September 16-19, 2026. The company plans to introduce new products for bunion treatment and broader midfoot and hindfoot applications, including the Lapiplasty® Lightning™ System and Tailorplasty™ MIS Tailor’s Bunion System. Additionally, Treace will present clinical data from significant studies on its ALIGN3D® Lapiplasty®, MTA3D® Adductoplasty®, and SPRINT™ SpeedPlate® technologies.
New bunion tools and five-year study results will be shown in Seattle
Treace Medical Concepts will showcase new product innovations and present clinical data at the 2026 AOFAS Annual Meeting in Seattle. The company will highlight advancements in its 3D bunion correction portfolio, including new instrumentation and a minimally invasive tailor's bunion system, along with new offerings for midfoot and hindfoot markets. Clinical results from 5-year ALIGN3D® Lapiplasty®, MTA3D® Adductoplasty®, and SPRINT™ SpeedPlate® studies will also be presented.
BlackRock Inc. Takes Position in Treace Medical Concepts, Inc. $TMCI
BlackRock Inc. has acquired a new position of 1.38 million shares, valued at $5.5 million, in Treace Medical Concepts (NASDAQ:TMCI) during the second quarter. Other institutional investors also increased their stakes in the company, with institutional ownership now at 84.08%. Despite beating revenue and EPS estimates in its latest earnings report, Treace Medical Concepts remains unprofitable, and analysts currently have a "Reduce" rating on the stock with an average price target of $5.17.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Recommendation of "Reduce" by Analysts
Analysts have issued a consensus "Reduce" rating for Treace Medical Concepts (NASDAQ:TMCI), with an average 12-month price target of $5.17. Despite the company exceeding quarterly revenue and EPS estimates, it remains unprofitable with a negative net margin. Notably, insiders, including the CEO, have recently purchased over 108,000 shares.
Treace Medical Concepts (NASDAQ:TMCI) CEO John Treace Acquires 39,944 Shares of Stock
Treace Medical Concepts (NASDAQ:TMCI) CEO John Treace purchased 39,944 shares of the company's stock on August 20th for $4.44 per share, totaling approximately $177,351. Following this acquisition, Treace now owns 7.39 million shares. The company recently reported better-than-expected quarterly revenue of $45.38 million and an adjusted loss of $0.24 per share, surpassing analyst estimates.
John Treace Acquires 5,000 Shares of Treace Medical Concepts (NASDAQ:TMCI) Stock
CEO John Treace recently acquired 5,000 shares of Treace Medical Concepts (NASDAQ:TMCI) for $21,750, increasing his total holdings to 7.39 million shares. The company's latest quarterly results surpassed revenue and EPS expectations, despite a cautious "Reduce" rating from analysts and an average price target of $5.17. Institutional investors hold a significant 84.08% stake in the medical technology firm.
Insider Buying: Treace Medical Concepts (NASDAQ:TMCI) CEO Acquires 11,000 Shares
Treace Medical Concepts CEO John Treace recently purchased 11,000 shares of the company's stock for $47,740, increasing his direct ownership to over 7.4 million shares. Despite the CEO's increased stake and the company beating Q2 analyst estimates for revenue and EPS, institutional investors own a significant portion of the company. However, analyst sentiment remains cautious, with an average "Reduce" rating and a consensus price target of $5.17.
Treace Medical (TMCI) CEO adds to stake with late‑August buys
John T. Treace, CEO and director of Treace Medical Concepts, Inc. (TMCI), purchased 55,944 shares of common stock in late August 2026 through open-market transactions. These purchases were made on August 20, 21, and 24, at weighted average prices between $4.34 and $4.44 per share, and were not conducted under a Rule 10b5-1 trading plan. The filing also detailed significant indirect holdings attributed to his spouse and various trusts, for which Mr. Treace disclaims beneficial ownership.
Weber Capital Management LLC ADV Takes $2.35 Billion Position in Treace Medical Concepts, Inc. $TMCI
Weber Capital Management LLC ADV has acquired a new stake of 589,617 shares, valued at approximately $2.35 billion, in Treace Medical Concepts, Inc. This position represents 0.91% of the company and 2.0% of Weber Capital Management's portfolio. Despite cautious analyst sentiment with a "Reduce" rating, Treace Medical Concepts reported a smaller-than-expected quarterly loss and higher-than-anticipated revenue, while institutional investors collectively own 84.08% of the company's stock.
Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates
Treace Medical Concepts (TMCI) reported a Q2 loss of $0.24 per share, surpassing the Zacks Consensus Estimate of a $0.3 loss, and exceeding revenue expectations with $45.38 million. The company's stock has seen a significant gain of 78.8% year-to-date, outperforming the S&P 500. Analysts currently assign TMCI a Zacks Rank #3 (Hold), anticipating market-level performance in the near future.
TMCI senior director charged with insider trading in U.S.
David Pidgeon, a senior director at Treace Medical Concepts, Inc. (TMCI), has been indicted for securities fraud based on insider trading. He allegedly used confidential information about TMCI's poor financial performance in October 2025 to purchase short-term put options before the company publicly announced a significant net loss and reduced revenue projections, leading to a stock price drop. Pidgeon faces a maximum of 45 years in prison across two securities fraud charges.
Did You Lose Money on Treace Medical Concepts, Inc. (TMCI)? Levi
Levi & Korsinsky LLP has filed a class action securities lawsuit against Treace Medical Concepts, Inc. (NASDAQ:TMCI) on behalf of investors who suffered losses due to alleged securities fraud between May 8, 2023, and May 7, 2024. The lawsuit claims that the company made false statements and concealed that competition negatively impacted demand for its "Lapiplasty" product, leading to revenue decline and necessitating alternative product development. Investors who lost money are urged to act before June 10, 2025, to learn about their rights to seek recovery.
522,900 Shares in Treace Medical Concepts, Inc. $TMCI Purchased by Renaissance Technologies LLC
Renaissance Technologies LLC acquired 522,900 shares of Treace Medical Concepts, Inc. ($TMCI) in the first quarter, valued at approximately $701,000, giving them a 0.81% stake. Other institutional investors also adjusted their holdings, with hedge funds and institutions collectively owning 84.08% of the company. Despite cautious analyst sentiment and a "Reduce" average rating, the company surpassed Q1 earnings expectations, reporting revenue of $45.38 million and a loss of $0.24 per share.
Armistice Capital (TMCI) discloses 6.36M-share Treace Medical ownership stake
Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership stake of 6,364,000 shares in Treace Medical Concepts, Inc. (TMCI), representing 9.79% of the outstanding common stock. This ownership is held directly by Armistice Capital Master Fund Ltd., with Armistice Capital serving as its investment manager, granting them shared voting and dispositive power over the shares. The filing specifies key figures such as the total shares beneficially owned, the percentage of the class, and the shared voting and dispositive powers.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50
Treace Medical Concepts (NASDAQ:TMCI) recently released its second-quarter report, showing revenues of US$45 million, beating expectations. Analysts have moderately uplifted their sentiment, upgrading loss per share forecasts and raising the consensus price target by 18% to US$5.50. Despite this, revenue growth is expected to slow significantly compared to historical performance and industry peers.
Treace Medical Concepts (TMCI) officer disposes shares for tax or exercise costs
Sean F. Scanlan, Chief Innovation Officer at Treace Medical Concepts (TMCI), reported a Form 4 transaction indicating the disposition of 9,814 shares of common stock. These shares were delivered or withheld to cover exercise price or tax liability. Following this transaction, Scanlan directly holds 679,863 shares, which includes restricted stock units and accounts for a transfer of shares to a former spouse.
Treace Medical Concepts (TMCI) CEO John T. Treace reports 19.2% beneficial stake
John T. Treace, CEO of Treace Medical Concepts, has filed an amended Schedule 13G indicating a 19.2% beneficial ownership stake in the company, totaling 12,530,959 shares. This ownership includes direct holdings, shares in family trusts, his spouse's holdings, and stock options exercisable within 60 days. The filing, based on 64,976,624 outstanding shares as of June 30, 2026, details both sole and shared voting and dispositive powers over these shares.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50
Treace Medical Concepts (NASDAQ:TMCI) recently released its Q2 earnings, with revenues exceeding expectations at US$45m and statutory losses coming in smaller than anticipated at US$0.24 per share. Following the report, analysts increased their price target for TMCI to US$5.50, reflecting a moderate uplift in sentiment despite expectations for slower revenue growth compared to the historical average and industry peers. The analysts reconfirmed loss per share estimates for next year, indicating improving intrinsic value for the business.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50
Treace Medical Concepts, Inc. (NASDAQ:TMCI) recently released its second-quarter report, showing revenues of US$45m, surpassing estimates by 3.3%, and statutory losses that were less than expected at US$0.24 per share. Following the report, analysts increased their consensus price target for TMCI by 18% to US$5.50, and slightly upgraded loss per share forecasts for the year. However, the company's revenue growth is projected to slow to 2.1% annually until the end of 2026, which is significantly lower than its historical 18% p.a. growth and slower than other industry participants.
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Rating of "Reduce" by Analysts
Analysts have issued a consensus "Reduce" rating for Treace Medical Concepts, Inc. (NASDAQ:TMCI), with an average 12-month price target of $5.17, despite the company beating recent quarterly revenue and EPS estimates. The stock opened at $4.67, and significant insider and institutional ownership is noted. Insiders have recently purchased a substantial amount of shares.
Treace Medical Concepts (NASDAQ:TMCI) Price Target Raised to $5.00 at Truist Financial
Truist Financial has increased its price target for Treace Medical Concepts (NASDAQ:TMCI) from $4.00 to $5.00, while maintaining a "hold" rating, suggesting a potential upside of 10.13%. Despite this, the broader analyst consensus remains "Reduce" with a target of $5.17. The company recently reported a narrower-than-expected loss and exceeded revenue estimates, with notable insider buying and significant institutional ownership.
Truist Securities Adjusts PT on Treace Medical Concepts to $5 From $4, Keeps Hold Rating
Truist Securities has raised its price target for Treace Medical Concepts (TMCI) from $4 to $5, while maintaining a "Hold" rating on the stock. This adjustment comes after Treace Medical Concepts recently increased its earnings guidance for the full-year 2026. The medical technology company specializes in surgical solutions for bunion and midfoot deformities.
Treace Medical Concepts: Q2 Earnings Snapshot
Treace Medical Concepts Inc. reported a Q2 loss of $15.9 million, or 24 cents per share, with revenue reaching $45.4 million. The orthopedic medical device company anticipates full-year revenue to be between $204 million and $212 million. This financial update was generated using data from Zacks Investment Research.
Treace Medical Concepts (TMCI) Stock Jumps As Cash Burn Eases But Sales Stall
Treace Medical Concepts (TMCI) saw its stock jump 8.7% despite essentially flat Q2 revenue of US$45.4m and a net loss of US$15.9m. Investors reacted positively to a smaller adjusted EBITDA loss and reduced cash burn, indicating a market preference for financial discipline over top-line growth. While bulls see potential in a broader foot and ankle platform, bears are concerned about mix pressures from lower-priced procedures impacting revenue and margins.
Treace Medical Concepts, Inc. (TMCI) Stock Price, News, Quote & History
This page provides a comprehensive overview of Treace Medical Concepts, Inc. (TMCI) stock, including its current price, after-hours trading, historical data, and key financial metrics. It also features company news, analyst ratings, and a detailed description of its medical devices and technologies, such as the Lapiplasty System and Nanoplasty 3D Minimally Invasive Bunion Correction System. The article outlines the company's performance overview, earnings trends, and comparative analysis with other medical device companies.
Treace Medical Concepts: Q2 Earnings Snapshot
Treace Medical Concepts Inc. (TMCI) reported a second-quarter loss of $15.9 million, equating to 24 cents per share. The orthopedic medical device maker generated $45.4 million in revenue for the period and expects full-year revenue to be between $204 million and $212 million. This financial report was generated using data from Zacks Investment Research.
Treace Medical Concepts (NASDAQ:TMCI) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS
Treace Medical Concepts (NASDAQ:TMCI) announced its quarterly earnings, reporting an adjusted loss of $0.24 per share, surpassing the consensus estimate of a $0.30 loss, with revenues of $45.38 million beating the $44.02 million forecast. The company raised its 2026 revenue guidance to $204 million–$212 million and improved its full-year adjusted EBITDA guidance to a loss of $3 million–$5 million. Despite a 4% year-over-year revenue decline due to a shift towards lower-priced minimally invasive products, TMCI's stock traded up 8.7% following the announcement.
Treace Medical Concepts earnings beat by $0.06, revenue topped estimates
Treace Medical Concepts (NASDAQ: TMCI) reported a second-quarter EPS of $-0.24, surpassing the analyst estimate of $-0.30 by $0.06. The company's revenue for the quarter reached $45.4 million, exceeding the consensus estimate of $43.94 million. Despite a 117.91% increase in its stock price over the last three months, the stock is down 28.55% in the last 12 months, and its financial health is rated as "good performance" by InvestingPro.
Treace Medical Concepts Releases Q2 2026 Financial Results
Treace Medical Concepts, Inc. (TMCI) reported a narrower Q2 2026 loss per share of -$0.24, beating the -$0.30 estimate by 20.0%. The company's revenue for the quarter was $45.4 million, representing a 4.0% year-over-year decrease. Management projects full-year revenue to be between $204.0 million and $212.0 million.
Press Release: Treace Medical Concepts Reports Second Quarter 2026 Financial Results
This press release details Treace Medical Concepts' financial results for the second quarter of 2026. It will likely cover key financial metrics such as revenue, net income, and earnings per share, as well as provide an outlook for future performance. The report will offer insights into the company's operational achievements and challenges during the period.
Treace Medical Concepts Inc (TMCI) (Q2 2026) Earnings Call Highlights: Revenue Declines 4% but ...
Treace Medical Concepts Inc (TMCI) reported a 4% revenue decline to $45.4 million in Q2 2026, though adjusted EBITDA loss narrowed and cash usage significantly decreased. The company is experiencing increased adoption of new bunion systems and expects improved performance in the latter half of 2026, driven by new product launches and seasonal strength. Full-year 2026 revenue guidance was raised, despite anticipated continued revenue declines through Q3 due to product mix shifts.
Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Navigating Challenges with Innovative Medical Solutions
Treace Medical Concepts (TMCI) is a healthcare company innovating in bunion and foot deformity correction with products like the Lapiplasty System. Despite financial challenges including negative revenue growth and ROE, the company's unique product offerings present potential for investors. Its stock shows volatility, and analyst sentiment is mixed, highlighting the balance between its pioneering medical solutions and current financial performance.
About 40% of Treace’s Lapiplasty surgeon users use new systems
Treace Medical Concepts reported a 4% decline in Q2 2026 revenue to $45.4 million year-over-year, alongside a net loss of $15.9 million. Despite the revenue dip, the company saw an 8% reduction in operating expenses and significantly decreased year-to-date cash usage by 57%. Treace also raised its full-year 2026 revenue guidance and improved its adjusted EBITDA loss outlook, noting increased adoption of its newer bunion systems among Lapiplasty surgeons.
Securities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) Investors - Contact Levi & Korsinsky Before June 10, 2025
Levi & Korsinsky LLP has filed a class action securities lawsuit against Treace Medical Concepts, Inc. (NASDAQ:TMCI). The lawsuit alleges that the company made false statements and concealed information regarding competition and demand for its Lapiplasty product, leading to revenue decline. Investors who suffered losses between May 8, 2023, and May 7, 2024, are encouraged to contact the firm before June 10, 2025, to learn about potential recovery.
Join Class Action to Recover Losses from Treace Medical Concepts
Levi & Korsinsky LLP has filed a class action securities lawsuit against Treace Medical Concepts, Inc. (TMCI) for alleged securities fraud between May 8, 2023, and May 7, 2024. The lawsuit claims that the company made false statements regarding competition impacting demand for its primary product, the Lapiplasty, leading to declining revenue. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky before June 10, 2025, to learn about their rights to seek recovery.
Treace Medical Concepts (TMCI) Expected to Post Earnings on Friday
Treace Medical Concepts (TMCI) is projected to release its Q2 2026 earnings before market open on Friday, August 7th, with analysts anticipating a loss of $0.30 per share and revenue of $44.02 million. Despite exceeding estimates in the previous quarter, the company remains unprofitable. Insider buying and institutional ownership are noted, while analyst sentiment generally recommends "Reduce" for the stock.
Treace Medical Concepts Number of Employees 2026 | Employee Count & Headcount Data
Treace Medical Concepts, Inc. (TMCI) has approximately 444 total employees worldwide as of March 2026, a 2.3% decline from 2023. The company is actively hiring with 28 job postings in 2026, though this represents a 48.6% decline from 2025. Its workforce is concentrated in the United States, and the largest functional group is Engineering.
BlackRock (TMCI holder) files amended 13G showing 959,320 Treace Medical shares
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 959,320 shares in Treace Medical Concepts, Inc., which represents 1.5% of the outstanding common stock. This filing indicates that BlackRock holds sole voting and dispositive power over these shares. While various underlying persons may have rights to dividends or sale proceeds, no single person possesses an interest exceeding five percent of Treace's outstanding common shares through these holdings.
Treace Medical Concepts Inc (TMCI) Institutional Confidence
The article provides an analysis of the institutional confidence score for Treace Medical Concepts Inc (TMCI), which currently stands at 5.00, ranking 107 out of 199 in its industry. Institutional shareholding proportion decreased by 4.20% quarter-over-quarter to 58.61%. James Simons is highlighted as the largest institutional shareholder, and a table details significant changes in holdings by other institutional investors.
